Global First Approval For Daiichi’s EZH1/2 Inhibitor Valemetostat In Japan
Ozoralizumab Also Gets First Nod
Japan has granted to the first approval worldwide to Daiichi Sankyo’s dual EZH1/2 inhibitor valemetostat, for the treatment of adult T-cell leukemia/lymphoma. Taisho’s trivalent anti-TNFα nanobody ozoralizumab also received its global first approval, as part a large new batch of regulatory nods in the country.
You may also be interested in...
Daiichi's Novel EZH Candidate Progresses In New Consortium Trial
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Daiichi’s EZH Contender Moves Ahead In Leukemia/Lymphoma
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.